Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, ...

Vibrant Therapeutics ("Vibrant"), a clinical-stage biotechnology company developing next-generation intelligent therapeutics, ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a ...

Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio's investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...

Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; ...

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...